Clinical trial · Interventional
Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants
The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants
NCT02027337CI-TRIAL-00016129unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We investigate parameters of hemocoagulation and lipoperoxidation in women using combined oral contraceptives with antiandrogenic activity (containing drospirenone with 20 or 30 mcg ethinylestradiol; or cyproterone acetate); correction of these changes by antioxidants
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hyperandrogenism | — | UNRESOLVED | — |
| Menstrual Irregularities | — | UNRESOLVED | — |
| Polycystic Ovarian Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 20 mcg ethinylestradiol /3 mg drospirenone | Drug | — | UNRESOLVED |
| 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit | Drug | — | UNRESOLVED |
| 30 mcg ethinylestradiol/3 mg drospirenone | Drug | — | UNRESOLVED |
| 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit | Drug | — | UNRESOLVED |
| 35 mcg ethinylestradiol/2 mg cyproterone | Drug | — | UNRESOLVED |
| 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- type
- NO_INTERVENTION
- label
- Control group
- description
- Healthy women that no use combined oral contraceptives
- type
- EXPERIMENTAL
- label
- 20 mcg EE/3 mg drospirenone
- description
- Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
- interventionNames
- Drug: 20 mcg ethinylestradiol /3 mg drospirenone
- type
- EXPERIMENTAL
- label
- 20 mcg EE/3 mg drospirenone and Selmevit
- description
- Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 18-35 years * Absence of contraindications for COC use * Informed voluntary consent for examination Exclusion Criteria: * Age younger than 18 and older than 35 years * Refusal or failure to comply with the study protocol * Drug or alcohol dependence * Psychiatric diseases * Severe somatic and allergic diseases * Pregnancy * Malignancies * Taking drugs that affect haemostasis, including hormonal contraceptives during 6 months before study beginning * Cases of thrombosis among first-line relatives in family history * Contraindications to the COC use under Eligibility Criteria of hormonal contraception (WHO, 2012)
References
Publications (0)
Data not yet available
No reference posted for this study.